ThinkEquity

Annovis Bio, Inc. is a clinical-stage pharmaceutical company based in Berwyn, Pennsylvania, specializing in the development of treatments for neurodegenerative disorders, particularly Alzheimer's disease and Parkinson's disease. The company is advancing several compounds in clinical trials, with its lead candidate, ANVS401, currently in Phase 2a trials aimed at treating Alzheimer’s disease, Parkinson’s disease, and other chronic neurodegenerative conditions. Additionally, Annovis is developing ANVS405, which focuses on providing neuroprotection following traumatic brain injuries and strokes, and ANVS301, which is in Phase I trials designed to enhance cognitive function in later stages of Alzheimer’s disease and dementia. Founded in 2008, Annovis Bio is dedicated to creating innovative therapies to address the challenges posed by these debilitating diseases.

Color Kinetics is a leader in the design and marketing of intelligent solid-state lighting systems, primarily utilizing light-emitting diodes (LEDs) as their light source. The company develops innovative lighting technologies that cater to diverse markets, including architectural applications, motion picture production, medical settings, and children's toys. By focusing on solid-state devices, Color Kinetics harnesses the advantages of advanced semiconductor materials to create efficient and versatile lighting solutions.